Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

1,129

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

January 6, 2020

Study Completion Date

June 22, 2020

Conditions
Smallpox
Interventions
BIOLOGICAL

FD MVA-BN

Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)

Trial Locations (12)

14609

Rochester Clinical Research, Inc., Rochester

20850

Optimal Research, LLC (Synexus), Rockville

27612

M3 Wake Research, Inc., Raleigh

32934

Optimal Research, LLC (Synexus), Melbourne

35294

University of Alabama at Birmingham, Birmingham

40536

University of Kentucky Healthcare Chandler Hospital, Lexington

52242

University of Iowa, Iowa City

61614

Optimal Research, LLC (Synexus), Peoria

63104

Saint Louis University, St Louis

63110

Washington University School of Medicine, St Louis

73112

Lynn Health Science Institute, Oklahoma City

02886

Omega Medical Research, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Bavarian Nordic

INDUSTRY

NCT03699124 - Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial | Biotech Hunter | Biotech Hunter